Zacks restated their neutral rating on shares of Stryker in a new report, according to an Intercooler Online report.
Zacks currently has a $97 price objective on the stock, according to an analyst, "Stryker Corp. reported disappointing fourth quarter 2014 results." However, the analyst noted, Stryker's acquisition-driven strategy is expected to boost its growth profile by expanding its existing product offerings across all business segments.
Additionally, the expected FDA approval for MAKO total knee in 2015 is estimated to result in meaningful sales in the long term, according to the report.
More articles on devices:
K2M sets follow-on offering at $18.75 per share — 5 things to know
Implanet's JAZZ technology receives intellectual patent protection in Europe
FTC makes second request for additional information on Wright Medical-Tornier merger — 5 points